ketoconazole has been researched along with rivaroxaban in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Becka, M; Kubitza, D; Mueck, W | 1 |
| Ge, W; Jiang, Q; Xu, R | 1 |
| Burhenne, J; Foerster, KI; Haefeli, WE; Lehmann, ML; Mikus, G; Schaumaeker, M | 1 |
| Chan, ECY; Cheong, EJY; Chua, DXY; Teo, DWX | 1 |
| Chan, ECY; Cheong, EJY; Chin, SY; Ng, DZW; Wang, Z | 1 |
| Bin, V; Delavenne, X; Hodin, S; Ollier, E; Saib, S | 1 |
2 trial(s) available for ketoconazole and rivaroxaban
| Article | Year |
|---|---|
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Topics: Adolescent; Adult; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Erythromycin; Humans; Ketoconazole; Metabolic Clearance Rate; Midazolam; Middle Aged; Morpholines; Rivaroxaban; Substrate Specificity; Thiophenes; Young Adult | 2013 |
Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.
Topics: Administration, Oral; Adolescent; Adult; Atrial Fibrillation; Case-Control Studies; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Factor Xa Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles; Young Adult | 2019 |
5 other study(ies) available for ketoconazole and rivaroxaban
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Computer Simulation; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Factor Xa Inhibitors; Humans; Ketoconazole; Liver Diseases; Male; Models, Biological; Renal Insufficiency; Ritonavir; Rivaroxaban | 2018 |
Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Computer Simulation; Drug Interactions; Humans; Ketoconazole; Kidney; Models, Biological; Organic Anion Transporters, Sodium-Independent; Rivaroxaban; Verapamil | 2019 |
Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism.
Topics: Cytochrome P-450 CYP3A; Drug Interactions; Erlotinib Hydrochloride; Humans; Ketoconazole; Models, Biological; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Rivaroxaban; Venous Thromboembolism | 2022 |
In Vitro Evaluation of P-gp-Mediated Drug-Drug Interactions Using the RPTEC/TERT1 Human Renal Cell Model.
Topics: Drug Interactions; Humans; Ketoconazole; Kidney; Reproducibility of Results; Rivaroxaban | 2022 |